Chemistry of Chiral Vitamin B₆ Analogs. IV. Syntheses of Chiral Pyridoxal and Pyridoxamine Analogs Having a Branched "Ansa Chain" between 2′- and 5′-Positions

Makoto Ando,* Yoji Tachibana, and Hiroyoshi Kuzuhara

The Institute of Physical and Chemical Research, Wako, Saitama 351

(Received June 13, 1981)

Racemic 15-formyl-14-hydroxy-5,5-dimethyl-2,8-dithia[9](2,5)pyridinophane (4), an analog of pyridoxal having a branched "ansa chain" between 2'- and 5'-positions, was synthesized from 2,5-bis(chloromethyl)-3-hydroxy-0,0'-isopropylidene-4-pyridinemethanol. Optical resolution of 4 was achieved via the formation of Schiff base with 3-amino-3-deoxy-1,2:5,6-di-0-isopropylidene-p-glucofranose, giving the levorotary enantiomer of 4 (4a). Racemic 15-aminomethyl-14-hydroxy-5,5-dimethyl-2,8-dithia[9](2,5)pyridinophane (5), the same type of pyridoxamine analog as 4, and its levorotary enantiomer were synthesized from the corresponding 4 and 4a. Both levorotary and dextrorotary enantiomers of 5 were also obtained by the optical resolution of the racemate via the formation of chiral dibenzoyltartaric acid salts of 5.

In the course of our study on mimics of vitamin B₆-dependent enzymes, we have prepared a new type of chiral analogs of pyridoxal (1),1) pyridoxamine (2),2) and pyridoxine (3)3) which have a straight "ansa chain" between 2'- and 5'-positions. In the presence of a suitable metal ion, 111) and 221) have proved very active in the enzyme-mimics reactions such as racemization or transamination of amino acids. Although such reactions proceed via the formation of Schiff base⁴⁾ stereospecifically and/or stereoselectively owing to the chirality of the B6 analogs used, the degree of such steric effects is rather limited in comparison to the corresponding enzymic reactions. This will be because the "ansa chain" to which the B₆ analogs owe their planer chirality is too small and separated too far from the reaction center in the transition state. This prompted us to replace the straight "ansa chain" by a more bulky one. We prepared new B₆ analogs having a branched "ansa chain".

This paper deals with 15-formyl-14-hydroxy-5,5-dimethyl-2,8-dithia[9](2,5)pyridinophane (4) and 15-aminomethyl-14-hydroxy-5,5-dimethyl-2,8-dithia[9]-(2,5)pyridinophane (5), a new type of pyridoxal and pyridoxamine analogs, and their optical resolution. The levorotary enantiomer of 5 (5a) was also obtained by derivation from the corresponding enantiomer of 4 (4a).

3,3-Dimethyl-1,5-pentanedithiol (6) was prepared by the reaction of 1,5-dibromo-3,3-dimethylpentane (7)5) with thiourea and subsequent alkaline hydrolysis. The ansa compound (8) was obtained by slow addition of a benzene solution of an equimolar mixture of 6 and 2,5-bis(chloromethyl)-3-hydroxy-0,0'-isopropylidene-4-pyridinemethanol (9)1) to a dilute solution of sodium ethoxide in ethanol at 0 °C. Removal of the isopropylidene group in 8 by acidic hydrolysis afforded an analog of pyridoxine (10), which was oxidized with manganese(IV) oxide in the presence of N,N-dimethyl-1,3-propanediamine in pyridinebenzene.6) The resulting Schff base was hydrolyzed with acid to give racemic 15-formyl-14-hydroxy-5,5-dimethyl-2,8-dithia[9](2,5)pyridinophane (4). The optical resolution of 4 was performed by forming the Schiff base (11) by treatment with 3-amino-3-deoxy-1,2:5,6-di-O-isopropylidene-D-glucofranose.1) Levorotary enantiomer of 4 (4a) was obtained by

recrystallization of one of the less soluble diastereomers of the Schiff base (11a) from benzene and subsequent acidic hydrolysis of 11a. Compounds 4 and 4a were treated with hydroxylamine in ethanol to give the corresponding (\pm) -oxime (12) and (-)-oxime (12a), respectively. Reduction of 12 and 12a to the corresponding pyridoxamine analogs, 5 and 5a, were performed with sodium (dihydrotrithio)borate in tetrahydrofuran, following the earlier synthesis of $2^{(2)}$

We also succeeded in the optical resolution of $\mathbf{5}$; that is, when $\mathbf{5}$ was treated with (-)-(R,R)-dibenzoyltartaric acid in ethanol, the crude (-)-dibenzoyltartaric acid salt of $\mathbf{5}$ (neutral equimolar salt) ($\mathbf{13a}$) contaminated with its diastereomeric salt was prepared. Owing to the poor solubility of the salt in the usual solvents, fractional crystallization of $\mathbf{13a}$ proved very difficult. Therefore, such crude $\mathbf{13a}$ was treated with aqueous sodium hydrogencarbonate to give crude $\mathbf{5a}$

$$\begin{array}{c} \text{CH}_{3} \\ \text{X-}(\text{CH}_{2})_{2}\text{-C-}(\text{CH}_{2})_{2}\text{-X} \\ \text{CH}_{3} \\ \text{C} \\ \text{C} \\ \text{C} \\ \text{H}_{3} \\ \text{C} \\ \text{$$

11: mixture of diastereomer 11a: (-)-form




Fig. 1. ORD and CD spectra of **4a** and **1** (1.76×10⁻⁴ M solution in MeCN at 21 °C.). **4a**: —, **1**: ----.

including a little (+)-enantiomer (5b). This was repeatedly treated as described above and gave 5a. Using (+)-(S,S)-dibenzoyltartaric acid in the same way resulted in (+)-enantiomer (5b). The physical properties, including optical rotation, of 5a obtained by the resolution of 5 completely agreed with those of 5a prepared from 12a.

In order to determine the absolute configuration of **4a**, its ORD and CD spectra were measured. They were very similar to those of **1** (Fig. 1), indicating that **4a** has the same configuration as **1** has. Because **1** had been shown to have S-configuration on the

basis of the results of X-ray analysis of (-)-pyridoxine analog (3) derived from 1,3 the absolute configuration of 4a was determined to be S. Therefore, 5a and 12a derived from 4a also had S-configuration and the enantiomer 5b had R-configuration.

Studies on the function of these new B_6 analogs with definite configuration are under way. These indicate that in some systems they are very superior to the former analogs, 1 and 2. The results will be reported in the near furture.

Experimental

All melting and boiling points are uncorrected. Optical rotations were measured with a Perkin-Elmer 241MC polarimater. UV, IR, and ¹H NMR spectra were recorded on a Hitachi 124 Spectrophotometer, a Shimadzu IR-27G infrared spectrophotometer, and a JEOL PS-100 spectrometer, respectively. ORD and CD spectra were obtained using a JASCO J20A automatic recording spectropolarimeter. Column chromatography was performed on a Merck silica gel 60 (No. 7734).

3,3-Dimethyl-1,5-pentanedithiol (6). A stirred mixture of 1,5-dibromo-3,3-dimethylpentane (7)⁵⁾ (64.8 g), thiourea (61.0 g), and water (45 ml) was refluxed for 20 h. A solution of potassium hydroxide (100 g) in water (200 ml) was added all at once to the resulting solution at room temperature, refluxed for 6 h with stirring, diluted with water, and extracted with ether. The aqueous layer was acidified with hydrochloric acid and extracted with ether. The ethereal extract was dried (MgSO₄), concentrated, and distilled, giving 35.8 g (82%) of 6: bp 100—101 °C/7 mmHg (1 mmHg \approx 133 Pa); n_2^{33} 1.5141; IR (film) 2550 cm⁻¹ (SH). Found: C, 50.84; H, 9.73; S, 39.07%. Calcd for $C_7H_{16}S_2$: C, 51.17; H, 9.81; S, 39.02%.

14-Hydroxy-15- hydroxymethyl - O,O' - isopropylidene - 5,5 - dimethyl-2,8-dithia[9](2,5)pyridinophane (8). A solution of 6 (4.6 g) and 2,5-bis(chloromethyl)-3-hydroxy-0,0'-isopropylidene-4-pyridinemethanol (9)1) (6.9 g) in benzene (500 ml) was added to a stirred solution of sodium ethoxide (prepared from sodium (1.7 g) in ethanol (2.5 l)) over a period of 6 h in an ice bath and kept overnight at 0 °C. The solvents were removed and the residue was extracted with chloroform-water. The organic layer was washed with water, dried (MgSO₄), concentrated, and chromatographed. Elution with dichloromethane gave 7.5 g (81%) of 8: mp 139— 140 °C; UV_{max} (MeCN) 297 (ε 6.3×10³) and 211 nm (ε 15.0×10³); ¹H NMR (CDCl₃) δ =7.94; (1H, s), 5.26 (1H, d, J=16 Hz), 4.77 (1H, d, J=16 Hz), 4.15 (1H, d, J=12 Hz), 3.73 (1H, d, J=12 Hz), 3.61 (1H, d, J=13 Hz), 3.50 (1H, d, J=13 Hz), 1.63 (3H, s), 1.59 (3H, s), and 0.70 (6H, s). Found: C, 61.23; H, 7.67; N, 3.92; S, 18.11%. Calcd for C₁₈H₂₇NO₂S₂: C, 61.15; H, 7.70; N, 3.96; S, 18.14%.

14-Hydroxy-15-hydroxymethyl-5,5-dimethyl-2,8-dithia[9](2,5)-pyridinophane (10). A stirred mixture of **8** (7.3 g) in 1 M (1 M=1 mol/dm³) hydrochloric acid (240 ml) was heated at 80—85 °C for 1 h. Soon **8** was dissolved and the hydrochloride of **10** was deposited. The mixture was made basic with solid sodium hydrogenearbonate and stirred for 1 h at room temperature. Separation of the precipitates gave 5.2 g of **10**. Additional **10** (1.2 g; total 99%) was recovered by concentrating the filtrate to dryness, extracting the residue with pyridine, and removing the pyridine; mp> 280 °C. Found: C, 57.49; H, 7.36; N, 4.30; S, 20.44%. Calcd for $C_{15}H_{23}NO_2S_2$: C, 57.47; H, 7.40; N, 4.47; S,

20.45%.

Hydrochloride: Mp 208—209 °C dec Found: C, 51.50; H, 6.90; Cl, 10.11; N, 3.97; S, 18.38%. Calcd for $C_{15}H_{24}$ -ClNO₂S₂: C, 51.49; H, 6.91; Cl, 10.13; N, 4.00; S, 18.32%.

 (\pm) -15-Formyl-14 - hydroxy - 5,5 - dimethyl - 2,8 - dithia[9](2,5)pyridinophane (4). A stirred mixture of N,N-dimethyl-1,3-propanediamine (7.2 ml), manganese(IV) oxide (27.0 g), and a solution of 10 (5.2 g) in pyridine (100 ml) and benzene (70 ml) was refluxed for 4 h while the generated water was azeotropically separated.⁶⁾ The insoluble material was filtered off with celite and the filtrate was evaporated to dryness. Dioxane (100 ml) and 1.2 M hydrochloric acid (65 ml) were added to the residue and stirred for 1 h at room temperature. Dilution of the solution with water (ca. 11) and adjustment of pH to ca. 3 with aqueous sodium hydroxide gave precipitates. These were passed through a silica-gel column with dichloromethane, giving 3.6 g (70%) of 4: mp 147—148 °C; IR (KBr) 1660 cm⁻¹ (C=O). Found: C, 57.82; H, 6.73; N, 4.41; S, 20.54%. Calcd for $C_{15}H_{21}$ NO_2S_2 : C, 57.85; H, 6.80; N, 4.50; S, 20.59%.

(-)-Schiff Base of 4 with 3-Amino-3-deoxy-1,2:5,6-di-O-isopropylidene-D-glucofranose (IIa). A solution of 4 (6.24 g) and 3-amino-3-deoxy-1,2:5,6-di-O-isopropylidene-D-glucofranose¹⁾ (5.74 g) in benzene (500 ml) was refluxed for 2 h while the generated water was azeotropically separated. Evaporating the solution to ca. 100 ml afforded crude 11a, which was recrystallized twice from benzene, giving 4.17 g (75% based on half of 4) of 11a: mp>280 °C; UV_{max} (CHCl₃) 353 nm (ε 4.9×10³); IR (KBr) 1660 cm⁻¹ (C=N); [α] $_{0}^{26}$ -337° (ε 0.392, CHCl₃). Found: C, 58.90; H, 7.30; N, 4.98; S, 11.37%. Calcd for C₂₇H₄₀N₂O₆S₂: C, 58.67; H, 7.29; N, 5.07; S, 11.60%.

(-)-15-Formyl-14-hydroxy-5,5-dimethyl-2,8-dithia[9](2,5)-pyridinophane (4a). To a solution of 11a (3.98 g) in dioxane (400 ml) was immediately added 1 M hydrochloric acid (60 ml). The mixture was stirred for 1 h at room temperature. Treating the solution as described in the preparation of 4 gave 1.80 g (80%) of 4a: mp 93 °C; [a]₂⁵ -422° (c 0.264, CHCl₃); UV_{max} (MeCN) 360 (ε 4.0× 10³), 248 (ε 8.2×10³), and 225 nm (ε 10.8×10³); IR (KBr) 1660 cm⁻¹ (C=O); ¹H NMR (CDCl₃) δ =10.53 (1H, s), 8.06 (1H, s), 4.35 (1H, d, J=12 Hz), 4.28 (1H, d, J=14 Hz), 3.77 (1H, d, J=14 Hz), 3.66 (1H, d, J=12 Hz), and 0.70 (6H, s). Found: C, 57.92; H, 6.78; N, 4.42; S, 20.57%. Calcd for C₁₅H₂₁NO₂S₂: C, 57.85; H, 6.80; N, 4.50; S, 20.59%.

(-) - 14 - Hydroxy - 15 - hydroxyiminomethyl - 5,5 - dimethyl - 2,8dithia[9](2,5) pyridinophane (12a). To a solution of 4a (1.22 g) in ethanol (60 ml) was immediately added solid hydroxylamine hydrochloride (0.38 g) and sodium acetate trihydrate (1.0 g). The mixture was stirred overnight at room temperature, concentrated to dryness, and extracted with chloroform-water. After being washed with aqueous sodium hydrogencarbonate and with water, the organic layer was dried (MgSO₄), concentrated, and chromatographed. Elution with chloroform afforded 1.01 g (79%) of **12a**: mp 218—219 °C; $[\alpha]_{D}^{23}$ -363° (c 0.204, CHCl₃); UV_{max} (MeCN) 330 (ε 4.6×10³), 260 (ε 9.9×10³), and 215 nm (ϵ 18.9×10³); IR (KBr) 3400 (OH) and 1660 cm⁻¹ (CH=N); ¹H NMR (CD₃SOCD₃) δ =12.28 (1H, s), 10.99 (1H, s), 8.73 (1H, s), 8.06 (1H, s), 4.28 (1H, d, J=12 Hz), 4.22 (1H, d, J=12 Hz), 3.77 (1H, d, J=13 Hz), 3.58 (1H, d, J=12 Hz), and 0.65 (6H, s). Found: C, 55.02; H, 6.80; N, 8.51; S, 19.54%. Calcd for $C_{15}H_{22}N_2O_2S_2$: C, 55.19; H, 6.79; N, 8.58; S, 19.64%.

 (\pm) - 14 - Hydroxy - 15 - hydroxyiminomethyl - 5,5 - dimethyl - 2,8-dithia[9](2,5)pyridinophane (12). Racemic isomer (4)

was treated as described in the treatment of **4a**, yielding **12** in 93% yield: mp 205—206 °C. Found: C, 55.05; H, 6.79; N, 8.40; S, 19.58%. Calcd for $C_{15}H_{22}N_2O_2S_2$: C, 55.19; H, 6.79; N, 8.58; S, 19.64%.

(-)-15-Aminomethyl-14 - hydroxy - 5,5 - dimethyl - 2,8 - dithia[9]-Dry THF (15 ml) was added (2,5) pyridinophane (5a). all at once to a stirred mixture of sulfur (675 mg) and sodium tetrahydroborate (264 mg) under nitrogen atmosphere and stirred for 1 h at room temperature. A solution of 12a (1.13 g) in dry THF (30 ml) was added to the mixture over a period of 20 min at room temperature with stirring and refluxed for 6 h. After removal of the solvent, the residue was dissolved in hot chloroform-methanol and extracted with dilute hydrochloric acid. The aqueous layer was treated with charcoal, made basic with solid sodium hydrogencarbonate, and extracted with chloroform. The organic layer was dried (MgSO₄), concentrated, and chromatographed. Elution with chloroform-methanol (9:1 v/v) gave 617 mg (57%) of **5a**: mp 174—175 °C dec; $[\alpha]_{D}^{25}$ -262° (c 0.409, CHCl₃); ORD: λ_{max} 314 ([\alpha] -1.32° × 10⁴), 285 ([α] +1.58°×10⁴), 247 ([α] -5.0°×10²), and 220 nm $([\alpha] + 4.8^{\circ} \times 10^{4})$ (c 6.4×10⁻⁵ M, MeCN, 21 °C); CD: λ_{max} 300 ($\Delta \varepsilon$ -22.3), 260 ($\Delta \varepsilon$ +1.65), and 239 nm ($\Delta \varepsilon$ -19.3) (c 6.4×10^{-5} M, MeCN, 21 °C); UV_{max} (MeCN) 299 (ϵ 5.7×10^3) and 214 nm (ε 14×10³); IR (KBr) 3350, 3200. and 3150 cm⁻¹ (NH₂, OH); ¹H NMR (CD₃SOCD₃) $\delta = 7.79$ (1H, s), 5.99 (2H, s), 4.18 (2H, s), 4.15 (1H, d, J=11 Hz), 3.78 (1H, d, J=13 Hz), 3.70 (1H, d, J=13 Hz), 3.45 (1H, d, J=11 Hz), and 0.64 (6H, s). Found: C, 57.45; H, 7.79; N, 8.79; S, 20.57%. Calcd for C₁₅H₂₄N₂OS₂: C, 57.65; H, 7.74; N, 8.96; S, 20.52%.

 (\pm) -15-Aminomethyl-14-hydroxy-5,5-dimethyl-2,8-dithia[9]-(2,5) pyridinophane (5). The racemate (12) was treated as described in the preparation of **5a**, affording **5** in 59% yield: mp 154—155 °C dec. Found: C, 57.37; H, 7.74; N, 8.80; S, 20.43%. Calcd for $C_{15}H_{24}N_2OS_2$: C, 57.65; H, 7.74; N, 8.96; S, 20.52%.

Optical Resolution of 5. (—)-Enantiomer of 5 (5a): A solution of (—)-(R,R)-dibenzoyltartaric acid (1.59 g) in ethanol (15 ml) was added to a hot solution of 5 (1.31 g) in ethanol (100 ml), concentrated to ca. 30 ml, and cooled in an ice bath. The precipitates were collected and stirred with a mixture of chloroform and saturated sodium hydrogencarbonate solution at room temperature for 1 h. The organic layer was washed with water, dried (MgSO₄), and concentrated to dryness, giving crude 5a. Two more treatments of the crude 5a with (—)-dibenzoyltartaric acid and sodium hydrogencarbonate, successively yielded 295 mg (45% based on half of 5) of 5a: mp 174—175 °C dec; $[\alpha]_D^{a}$ —262° (c 0.327, CHCl₃).

(-)-Dibenzoyltartarate of 5a (13a): Mp >280 °C; [α] $_{10}^{22}$ -186° (c 0.273, DMF). Found: C, 59.18; H, 5.70; N, 4.14; S, 9.52%. Calcd for $C_{33}H_{38}N_2O_9S_2$: C, 59.09; H, 5.71; N, 4.18; S, 9.56%.

(+)-Enantiomer of **5** (**5b**): By the use of (+)-(S,S)-dibenzoyltartaric acid instead of (-)-optical isomer, **5b** was obtained in 43% yield (based on half of **5**): mp 174—175 °C dec; [α]₁₀ +262° (ϵ 0.330, CHCl₃). Found: C, 57.37; H, 7.74; N, 8.78; S, 20.46%. Calcd for C₁₅H₂₄-N₂O₂S₂: C, 57.65; H, 7.74; N, 8.96; S, 20.52%.

(+)-Dibenzoyltartarate of **5b** (**13b**): Mp > 280 °C; $[\alpha]_D^{ab}$ +187° (ε 0.330, DMF). Found: C, 59.19; H, 5.65; N, 4.10; S, 9.55%. Calcd for $C_{33}H_{38}N_2O_9S_2$: C, 59.09; H, 5.71; N, 4.18; S, 9.56%.

The authors wish to express their thanks to Dr. Haruo Homma and his assistants for elementary

analyses and to Dr. Jun Uzawa and Mrs. Tamiko Chijimatsu for measurements of ¹H NMR spectra.

References

- 1) Part I of this series: H. Kuzuhara, M. Iwata, and
- S. Emoto, *J. Am. Chem. Soc.*, **99**, 4173 (1977).

 2) Part II of this series: H. Kuzuhara, T. Komatsu, and S. Emoto, Tetrahedron Lett., 1978, 3563.
- 3) Part III of this series: T. Sakurai, H. Kuzuhara,
- and S. Emoto, Acta Crystallogr., Sect. B, 35, 2984 (1979).
 4) E. E. Snell and S. J. Di Mari, "The Enzyme," 3rd ed, ed by P. D. Boyer, Academic press, New York and London (1970), Vol. 2, Chap. 7, p. 335.
 5) A. T. Blomquist, E. S. Wheeler, and Y. Chu, J. Am.
- Chem. Soc., 77, 6307 (1955).
 - 6) M. Iwata, Bull. Chem. Soc. Jpn., 54, 2835 (1981).